Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback